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In this issue, the review article by van der Aalst et al (ref), focuses on our current 
understanding of lung cancer computed tomography (CT) screening. It outlines key 
unanswered questions and briefly addresses the issue of screening implementation. 
The article adds to at least seven national and international statements providing 
recommendations on CT lung cancer screening.   
 
To date there are no recommendations on how to implement a lung cancer CT 
screening programme within a national health service model.  Clearly lung cancer 
screening implementation will be different from breast or colon screening because of 
our ability to more precisely define the risk of lung cancer and therefore inclusion 
criteria will be more than just age and sex. The US Preventive Services Task Force 
recommended similar inclusion criteria to the National Lung Screening Trial (NLST) 
and most other US recommendations follow suit with only the National 
Comprehensive Cancer Network including risk factors other than smoking and age 
[2]. The UK Lung Screen trial used the LLPv2 risk model and demonstrated that high 
risk individuals could be recruited with 2.1% lung cancer detection after a single 
screen, equivalent to 3 annual screens in NLST [3]. The PLCOm2012 risk model was 
tested on the NLST data and demonstrated that >12% more cancers would have been 
identified using this model [4] .   
 
The pragmatic use of risk prediction models has not been evaluated in the lung cancer 
screening setting.  One issue may be the availability of sufficient accurate data with 
which to populate the model. This will include accurate and up to date data on 
smoking status, as the most influential risk factor. Possible ways to acquire data are 
through primary care, or at a national level through invitation letters to all individuals 
within a specified age band.   Data completeness is an issue with the former and 
participation an issue with the latter (due to language or educational barriers and the 
fact that many high-risk people will be in the more socioeconomically deprived 
groups where participation is lower [5]). Innovative uses of technology and 
messaging services on which the population could update their risk data may be an 
option, but the older population in the lung cancer screening setting may, not embrace 
this technology and a more tailored, personalised approach may be necessary. 
Obtaining risk data on individual patients presents our first major challenge. 
 
A second major challenge, not dealt with in the paper by van der Aalst (Ref 1), is 
participation. If lung cancer screening is to make a significant impact on the mortality 
from lung cancer, sufficient numbers of the population at risk of lung cancer will need 
to participate.  There is good evidence that this will be lower than for breast cancer 
and bowel cancer because lung cancer is over-represented in the more deprived 
socioecomomic groups, where participation rates in health interventions such as 
smoking cessation [6] and screening [7]  is known to be low. Methods to increase 
engagement with this group need to be developed to increase the overall efficacy of 
screening. 
 
A third major challenge is the availability of CT scanners and the pressure on 
radiological services. Most of the CT equipment in the UK is located in busy 
secondary care institutions.  Suitable access to CT scanners needs to be determined, 
including whether mobile CT scanners would be more appropriate to engage the hard 
to reach community, which opens the question of the investment required to set up 
this infrastructure.  
 
The health service community have not to date quantified the additional radiological 
services required to report annual and follow up CT scans as part of a national 
screening programme, but clearly some addition to the radiology workforce will be 
required. Innovative approaches may need to be considered, such as whether 
screening CT images could be read by radiographers [8] or specialist trained clinical 
scientists, working under a Lead Radiologist, possibly in national CT reading centers.   
Training and  accreditation requirements for CT screen readers will have to be 
considered,  including in the use of volumetric analysis of lung nodules as has been 
used in European Lung Cancer Screening Trials  [3, 9, 10]. A national repository of 
CT lung cancer screening images could play an important role in this process.  
Ongoing quality assurance programmes evaluating readers’ false positive and false 
negative rates will also need to be developed. Finally, effort needs to be devoted to 
making the process of CT reporting and the communication of CT results as efficient 
as possible. For example standardised reporting templates, rapid access to historical 
imaging, and seamless integration with radiology information systems will all have a 
role to play in achieving this. 
 
The fourth major challenge, as discussed by van der Aalst et al (ref 1), is how to 
undertake integrated smoking cessation with lung cancer screening. If an annual scan 
is the preferred way forward, there will be a unique opportunity to regularly update 
patient smoking records and, if accepted, provide the necessary interventions. The 
current review shows that this has not been resolved.  
 
All of the current CT screening programmes have identified ‘significant other 
findings’, at varying percentages, which should be considered as an added potential 
benefit to the patient for participating in the screening programme. However, we are 
not yet in a position to fully utilise the CT image data to diagnose coronary heart 
disease and COPD, which when combined kill a larger number of individuals than 
lung cancer alone. This is our fifth major challenge and needs to be the focus of future 
demonstration projects. 
 
These issues need addressing urgently, if we are to achieve the potential further 
control of lung cancer via early detection [11]. 
  
[Reference 1 will be van der Aalst et al.] 
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